Search Result

Results for "

uric acid,hypoxanthine

" in MedChemExpress (MCE) Product Catalog:

By Targets:	Akt (1) Amylin Receptor (1) Amyloid-β (1) Angiotensin-converting Enzyme (ACE) (1) Antibiotic (2) Apoptosis (5) Bacterial (2) BCRP (1) Biochemical Assay Reagents (2) Cadherin (1) Calcium Channel (2) Caspase (1) CD38 (1) CGRP Receptor (2) Chemerin Receptor (1) Collagen (1) COX (1) Cytochrome P450 (3) Drug Derivative (5) Drug Metabolite (2) Endogenous Metabolite (21) Environmental Pollutants (1) Ephrin Receptor (1) ERK (2) Ferroportin (1) Fungal (1) FXR (1) GCGR (13) GLP Receptor (16) GLUT (8) GSK-3 (1) Interleukin Related (8) Isotope-Labeled Compounds (5) JNK (1) Lipoxygenase (1) MAP3K (1) MARCKS (2) Melanocortin Receptor (1) MOFs (2) mTOR (2) Natriuretic Peptide Receptor (NPR) (1) Neuropeptide Y Receptor (1) NF-κB (3) NOD-like Receptor (NLR) (6) Nucleoside Antimetabolite/Analog (1) OAT (1) Opioid Receptor (1) Oxidative Phosphorylation (1) PD-1/PD-L1 (2) Peptide-Drug Conjugates (PDCs) (1) Phosphatase (1) Phosphodiesterase (PDE) (1) Phospholipase (1) PI3K (1) PKC (2) Potassium Channel (2) PPAR (1) Reactive Oxygen Species (ROS) (13) Reference Standards (12) Renin (1) ROR (1) RXFP Receptor (1) TGF-β Receptor (1) TNF Receptor (2) Toll-like Receptor (TLR) (1) URAT1 (18) Vasopressin Receptor (3) Wnt (1) Xanthine Oxidase (25) β-catenin (1)
By Research Areas:	Cancer (15) Cardiovascular Disease (12) Endocrinology (5) Infection (3) Inflammation/Immunology (46) Metabolic Disease (79) Neurological Disease (8)

By Targets:

Akt (1)

Amylin Receptor (1)

Amyloid-β (1)

Angiotensin-converting Enzyme (ACE) (1)

Antibiotic (2)

Apoptosis (5)

Bacterial (2)

BCRP (1)

Biochemical Assay Reagents (2)

Cadherin (1)

Calcium Channel (2)

Caspase (1)

CD38 (1)

CGRP Receptor (2)

Chemerin Receptor (1)

Collagen (1)

COX (1)

Cytochrome P450 (3)

Drug Derivative (5)

Drug Metabolite (2)

Endogenous Metabolite (21)

Environmental Pollutants (1)

Ephrin Receptor (1)

ERK (2)

Ferroportin (1)

Fungal (1)

FXR (1)

GCGR (13)

GLP Receptor (16)

GLUT (8)

GSK-3 (1)

Interleukin Related (8)

Isotope-Labeled Compounds (5)

JNK (1)

Lipoxygenase (1)

MAP3K (1)

MARCKS (2)

Melanocortin Receptor (1)

MOFs (2)

mTOR (2)

Natriuretic Peptide Receptor (NPR) (1)

Neuropeptide Y Receptor (1)

NF-κB (3)

NOD-like Receptor (NLR) (6)

Nucleoside Antimetabolite/Analog (1)

OAT (1)

Opioid Receptor (1)

Oxidative Phosphorylation (1)

PD-1/PD-L1 (2)

Peptide-Drug Conjugates (PDCs) (1)

Phosphatase (1)

Phosphodiesterase (PDE) (1)

Phospholipase (1)

PI3K (1)

PKC (2)

Potassium Channel (2)

PPAR (1)

Reactive Oxygen Species (ROS) (13)

Reference Standards (12)

Renin (1)

ROR (1)

RXFP Receptor (1)

TGF-β Receptor (1)

TNF Receptor (2)

Toll-like Receptor (TLR) (1)

URAT1 (18)

Vasopressin Receptor (3)

Wnt (1)

Xanthine Oxidase (25)

β-catenin (1)

By Research Areas:

Cancer (15)

Cardiovascular Disease (12)

Endocrinology (5)

Infection (3)

Inflammation/Immunology (46)

Metabolic Disease (79)

Neurological Disease (8)

132

Inhibitors & Agonists

Biochemical Assay Reagents

Peptides

Natural
Products

Isotope-Labeled Compounds

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-B2130

Uric acid Maximum Cited Publications 21 Publications Verification	Environmental Pollutants Endogenous Metabolite Reactive Oxygen Species (ROS)	Cardiovascular Disease Inflammation/Immunology
Uric acid, scavenger of oxygen radical, is a very important antioxidant that help maintains the stability of blood pressure and antioxidant stress. Uric acid can remove reactive oxygen species (ROS) such as singlet oxygen and peroxynitrite, inhibiting lipid peroxidation .

HY-P0014

Liraglutide Maximum Cited Publications 38 Publications Verification	GCGR GLP Receptor	Metabolic Disease Cancer
Liraglutide is a glucagon-like peptide-1 (GLP-1) receptor agonist used clinically to treat type 2 diabetes mellitus.

HY-B2130A

Uric acid sodium Maximum Cited Publications 21 Publications Verification Monosodium urate	Reactive Oxygen Species (ROS) Endogenous Metabolite	Cardiovascular Disease Metabolic Disease
Uric acid sodium (Monosodium urate), scavenger of oxygen radical, is a very important antioxidant that help maintains the stability of blood pressure and antioxidant stress. Uric acid sodium can remove reactive oxygen species (ROS) such as singlet oxygen and peroxynitrite, inhibiting lipid peroxidation .

HY-P3462

Cagrilintide 3 Publications Verification	CGRP Receptor	Metabolic Disease
Cagrilintide is an investigational novel long-acting acylated amylin analogue, acts as nonselective amylin receptors (AMYR) and calcitonin G protein-coupled receptor (CTR) agonist. Cagrilintide induces significant weight loss and reduces food intake. Cagrilintide has the potential for the research of obesity .

HY-P2755

Xanthine oxidase, Microorganism 5+ Cited Publications XO; XOD	Reactive Oxygen Species (ROS)	Inflammation/Immunology Endocrinology
Xanthine oxidase, Microorganism (XO) is a xanthine oxidoreductase enzyme that generates reactive oxygen species (ROS), catalyzes the oxidation of hypoxanthine to xanthine, and further catalyzes the oxidation of xanthine to uric acid .

HY-P2755A

Xanthine oxidase, bovine milk	Reactive Oxygen Species (ROS)	Inflammation/Immunology Endocrinology
Xanthine oxidase, bovine milk is a xanthine oxidoreductase enzyme that generates reactive oxygen species (ROS), catalyzes the oxidation of hypoxanthine to xanthine, and further catalyzes the oxidation of xanthine to uric acid .

HY-113063

3-Methyl-2-oxovaleric acid 3 Publications Verification	Endogenous Metabolite	Metabolic Disease
3-Methyl-2-oxovaleric acid is a degradation product from Isoleucine. 3-Methyl-2-oxovaleric acid is a biomarker of mustard airway diseases (MADs) and uric acid stone .

HY-B2130S1

Uric acid-15N2	Endogenous Metabolite Reactive Oxygen Species (ROS)	Inflammation/Immunology
Uric acid- ¹⁵N₂ is the ¹⁵N labeled Uric acid . Uric acid, scavenger of oxygen radical, is a very important antioxidant that help maintains the stability of blood pressure and antioxidant stress. Uric acid can remove reactive oxygen species (ROS) such as singlet oxygen and peroxynitrite, inhibiting lipid peroxidation .

HY-W011711

Benzarone	URAT1 Oxidative Phosphorylation Apoptosis	Metabolic Disease
Benzarone is an oral inhibitor of human urate transporter 1 (hURAT1) with an IC₅₀ value of 2.8 μM, and it also acts as an uncoupler of oxidative phosphorylation. Benzarone can cause liver damage and promote cell apoptosis and necrosis. Benzarone can be used to lower serum uric acid levels and for research in vascular diseases .

HY-14874

Topiroxostat 5+ Cited Publications FYX-051	MOFs Xanthine Oxidase Cytochrome P450	Metabolic Disease
Topiroxostat (FYX-051) is a potent and orally active xanthine oxidoreductase (XOR) inhibitor with an IC₅₀ value of 5.3 nM and a K_i value of 5.7 nM. Topiroxostat exhibits weak CYP3A4-inhibitory activity (18.6%). Topiroxostat has the potential for hyperuricemia treatment .

HY-P2231

Cotadutide 1 Publications Verification MEDI0382	GCGR	Metabolic Disease
Cotadutide (MEDI0382) is a potent dual agonist of glucagon-like peptide-1 (GLP-1) and GCGR with EC₅₀ values of 6.9 pM and 10.2 pM, respectively. Cotadutide exhibits ability to facilitate both weight loss and glycaemic control, and alleviate fibrosis. Cotadutide can be used in the research of obesity and type 2 diabetes (T2D) .

HY-P2231A

Cotadutide acetate 1 Publications Verification MEDI0382 acetate	GCGR	Metabolic Disease
Cotadutide (MEDI0382) acetate is a potent dual agonist of glucagon-like peptide-1 (GLP-1) and GCGR with EC₅₀ values of 6.9 pM and 10.2 pM, respectively. Cotadutide acetate exhibits ability to facilitate both weight loss and glycaemic control, and alleviate fibrosis. Cotadutide acetate can be used in the research of obesity and type 2 diabetes (T2D) .

HY-15933

TOPS 1 Publications Verification	Biochemical Assay Reagents	Others Metabolic Disease
TOPS is a chromogenic substrate. TOPS undergoes an oxidative coupling reaction with 4-aminoantipyrine in the presence of H₂O₂ and nanocrystalline cobalt selenide. TOPS is used in studies related to uric acid detection .

HY-108844

Rasburicase	Xanthine Oxidase	Metabolic Disease Cancer
Rasburicase is a recombinant form of urate oxidase that works by catalyzing the oxidation of uric acid to allantoin, which has a higher solubility. Rasburicase specifically degrades uric acid, rapidly lowers blood uric acid levels, and improves inflammation and kidney damage caused by uric acid crystal deposition. Rasburicase can effectively lower uric acid and prevent uric acid nephropathy, and is used in the study of severe hyperuricemia associated with tumor lysis syndrome (TLS) and refractory gout .

HY-W012658

2-Methylacetophenone O-Methylacetophenone	Xanthine Oxidase	Metabolic Disease Inflammation/Immunology
2-Methylacetophenone (O-Methylacetophenone), acetophenone derivative and acaricide, is a xanthine dehydrogenase (XDH) inhibitor. 2-Methylacetophenone competitively binds to the XDH active site, blocking the pathway for xanthine to be converted to uric acid. 2-Methylacetophenone can be used for the study of hyperuricemia and house dust .

HY-P2921

Uricase, Microorganism Uox, Microorganism	Endogenous Metabolite	Metabolic Disease Inflammation/Immunology
Uricase, Microorganism (Uox, Microorganism) is a uricase (urate oxidase) derived from Microorganism. Uricase, Microorganism converts uric acid into allantoin. The absence of Uricase in mammals causes kidney diseases resulting from uric acid accumulation. Uricase, Microorganism can be used for research on chronic refractory gout and hyperuricemia .

HY-W017386

3-Methyl-2-oxovaleric acid sodium 3 Publications Verification	Endogenous Metabolite	Metabolic Disease
3-Methyl-2-oxovaleric acid sodium is a degradation product from Isoleucine. 3-Methyl-2-oxovaleric acid sodium is a biomarker of mustard airway diseases (MADs) and uric acid stone .

HY-P3291

Dapiglutide 1 Publications Verification ZP7570	GCGR	Metabolic Disease
Dapiglutide (ZP7570) is a long-acting glucagon-like peptide-1 receptor 1R (GLP-1R)/Glucagon-like peptide-2 receptor (GLP-2R) dual agonist. Dapiglutide alleviates intestinal dysfunction in a mouse short bowel model and has anti-obesity effects .

HY-B2130S

Uric acid-13C,15N3	Reactive Oxygen Species (ROS) Endogenous Metabolite	Inflammation/Immunology
Uric acid- ¹³C, ¹⁵N₃ is the ¹³C-labeled and ¹⁵N-labeled Uric acid. Uric acid, scavenger of oxygen radical, is a very important antioxidant that help maintains the stability of blood pressure and antioxidant stress. Uric acid can remove reactive oxygen species (ROS) such as singlet oxygen and peroxynitrite, inhibiting lipid peroxidation .

HY-W506071

3,7-Dimethyluric acid	Drug Derivative	Others
3,7-Dimethyluric acid is a methyl derivative of uric acid .

HY-B1514

Allantoic acid 1 Publications Verification	Endogenous Metabolite	Others
Allantoic acid is a degradative product of uric acid and associated with purine metabolism .

HY-147422

Xininurad XNW3009	URAT1	Metabolic Disease Inflammation/Immunology
Xininurad is a potent orally active URAT1 inhibitor with an IC₅₀ of 7.17 nM. Xininurad inhibits URAT1 activity to reduce serum uric acid levels and increase urinary uric acid excretion. Xininurad can be used for the research of hyperuricemia and gout .

HY-126061

1,7-Dimethyluric acid	Biochemical Assay Reagents Drug Metabolite	Others
1,7-Dimethyluric acid is an N-methylated uric acid and purine derivative, as well as a caffeine metabolite. When 1,7-Dimethyluric acid is acted upon by peroxidase in the presence of H₂O₂, it follows the same oxidation pathway to generate a UV-absorbing intermediate, which decays via first-order kinetics. 1,7-Dimethyluric acid can adsorb onto pyrolytic graphite electrodes, but not onto glassy carbon electrodes or platinum electrodes. The N-methylation modification of its pyrimidine ring prevents ring contraction of the diol intermediate, and no NMR evidence of O-alkylation is observed during propylation under the test conditions .

HY-P10218

MANS peptide 1 Publications Verification	MARCKS PKC	Inflammation/Immunology Cancer
MANS peptide is an inhibitor for myristoylated alanine-rich C kinase substrate (MARCKS), which competes with MARCKS in cells for membrane binding, and thus inhibits the stimulation of mucin secretion and tumor metastasis .

HY-W001542

5-Hydroxyoxindole	Reactive Oxygen Species (ROS)	Neurological Disease Metabolic Disease Cancer
5-Hydroxyoxindole is a structural analog of uric acid for its antioxidant. 5-Hydroxyoxindole has DPPH radical scavenging activities and lipid peroxidation-inhibitory activities. 5-Hydroxyoxindole is a product of partial metabolism of tryptophan involving conversion in the gut lumen of tryptophan to indole through the action of bacterial tryptophanase and tryptophan synthase. 5-Hydroxyoxindole is one of the main molecules responsible for the neurological symptoms of hepatic encephalopathy in rats. 5-Hydroxyoxindole can be used for the research of oxidative stress-mediated disorders .

HY-P2921C

Uricase (Recombinant) Uox (Recombinant)	Endogenous Metabolite	Metabolic Disease Inflammation/Immunology
Uricase (Recombinant) (Uox (Recombinant)) is a uricase (urate oxidase). Uricase (Recombinant) converts uric acid into allantoin. The deficiency of Uricase in mammals causes kidney diseases resulting from uric acid accumulation. Uricase (Recombinant) can be used for research on chronic refractory gout and hyperuricemia .

HY-W011258

H-Tyr-Phe-OH L-Tyrosyl-L-phenylalanine	Xanthine Oxidase Angiotensin-converting Enzyme (ACE)	Inflammation/Immunology Cancer
H-Tyr-Phe-OH (L-Tyrosyl-L-phenylalanine) is an orally active inhibitor of Angiotensin converting enzyme (ACE), with an inhibiton rate of 48% at 50 μM. H-Tyr-Phe-OH can be used as an biomarker for differentiating benign thyroid nodules (BTN) from thyroid cancer (TC). H-Tyr-Phe-OH exhibits xanthine oxidase inhibition (uric acid lowering) activity and serves as regulator in IL-8 production in neutrophil-like cells .

HY-139585

Tigulixostat LC350189	Xanthine Oxidase	Metabolic Disease
Tigulixostat (LC350189) is an orally active non-purine selective xanthine oxidase inhibitor. Tigulixostat has IC₅₀ values of 0.003 µM and 0.073 µM in bovine milk and rat plasma, respectively. Tigulixostat can effectively reduce serum uric acid levels and can be used in the research of gout and hyperuricemia .

HY-B2130R

Uric acid (Standard)	Reference Standards Reactive Oxygen Species (ROS) Endogenous Metabolite	Inflammation/Immunology
Uric acid (Standard) is the analytical standard of Uric acid. This product is intended for research and analytical applications. Uric acid, scavenger of oxygen radical, is a very important antioxidant that help maintains the stability of blood pressure and antioxidant stress. Uric acid can remove reactive oxygen species (ROS) such as singlet oxygen and peroxynitrite, inhibiting lipid peroxidation .

HY-113063R

3-Methyl-2-oxovaleric acid (Standard)	Reference Standards Endogenous Metabolite	Metabolic Disease
3-Methyl-2-oxovaleric acid (Standard) is the analytical standard of 3-Methyl-2-oxovaleric acid (HY-113063). This product is intended for research and analytical applications. 3-Methyl-2-oxovaleric acid is a degradation product from Isoleucine. 3-Methyl-2-oxovaleric acid is a biomarker of mustard airway diseases (MADs) and uric acid stone.

HY-P10218A

MANS peptide TFA 1 Publications Verification	MARCKS PKC	Inflammation/Immunology Cancer
MANS peptide TFA is the TFA salt form of MANS peptide (HY-P10218). MANS peptide TFA is an inhibitor for myristoylated alanine-rich C kinase substrate (MARCKS), which competes with MARCKS in cells for membrane binding, and thus inhibits the stimulation of mucin secretion and tumor metastasis .

HY-145453

Propacetamol	Interleukin Related	Inflammation/Immunology
Propacetamol is an orally active prodrug of Acetaminophen (HY-66005), which exerts antipyretic and analgesic effects after metabolism. Propacetamol reduces Aspirin (ASA) (HY-14654)-induced elevation of malondialdehyde (MDA) in gastric mucosa and plasma, regulates the levels of gastric mucosal glutathione (GSH and GSSG) to maintain cellular antioxidant defense, and increases gastric mucosal uric acid (UA) levels. Propacetamol exerts a dose-dependent protective effect against ASA-induced gastric mucosal damage in rats. Propacetamol can be used for the study of gastric mucosal injury by interfering with oxidative stress .

HY-P0014B

Liraglutide TFA Maximum Cited Publications 38 Publications Verification	GLP Receptor	Metabolic Disease
Liraglutide (TFA) is an agonist of glucagon-like peptide 1 receptor (GLP-1). Liraglutide (TFA) can activate GLP-1, leading to the release of insulin in the presence of increased glucose concentration. Liraglutide (TFA) also reduces glucagon secretion in a glucose-dependent manner. Liraglutide (TFA) can be studied in research on type 2 diabetes .

HY-P2921D

Uricase, candida utilis Uox, candida utilis	Endogenous Metabolite	Metabolic Disease Inflammation/Immunology
Uricase, candida utilis (Uox, candida utilis) is a uricase (urate oxidase) derived from Candida utilis. Uricase, candida utilis converts uric acid into allantoin. The absence of Uricase in mammals causes kidney diseases resulting from uric acid accumulation. Uricase, candida utilis can be used for research on chronic refractory gout and hyperuricemia .

HY-W017389R

Xanthine (Standard)	Reference Standards Endogenous Metabolite	Inflammation/Immunology
Xanthine (Standard) is the analytical standard of Xanthine. This product is intended for research and analytical applications. Xanthine, a plant alkaloid found in tea, coffee, and cocoa, is a mild stimulant of the central nervous system. Xanthine also acts as an intermediate product on the pathway of purine degradation . In Vitro: A number of stimulants are derived from Xanthine including caffeine and theobromine. Xanthine is a product on the pathway of purine degradation. Xanthine is subsequently converted to uric acid by the action of the Xanthine oxidase enzyme.

HY-135319

Strictinin	Bacterial Antibiotic ERK JNK NF-κB ROR Apoptosis Caspase GSK-3 Akt PI3K	Infection Metabolic Disease Inflammation/Immunology Cancer
Strictinin is an orally active phenolic compound. Strictinin reduces xanthine oxidase activity, uric acid production, and the activation of ERK1/2, JNK, NF-κB, and NLRP3 inflammasome components in hepatocytes treated with Xanthine (HY-W017389). Strictinin decreases elevated serum uric acid levels and enhanced xanthine oxidase activity in mice treated with potassium oxonate. Strictinin acts as a ROR1 inhibitor and exhibits anticancer activity against highly aggressive non-androgen-dependent prostate cancer. Strictinin induces cancer cell apoptosis (apoptosis), arrests cell cycle, and inhibits cancer cell migration, invasion, and epithelial-mesenchymal transition. Strictinin modulates gut microbiota, inhibits bacterial growth and biofilm formation, accelerates small intestinal transit, and blocks viral entry and replication. Strictinin can be used in research related to hyperuricemia, androgen receptor-negative non-androgen-dependent prostate cancer, triple-negative breast cancer, bacterial infections, constipation, coronavirus infections, dental caries, and infections caused by influenza A, influenza B, and human parainfluenza virus type 1 .

HY-W770183

Uric acid-13C3	Isotope-Labeled Compounds	Others
Uric acid- ¹³C₃ is ¹³C-labeled Uric acid (HY-B2130). Uric acid is the end product of purine metabolism in the human body. Uric acid can scavenge reactive oxygen species (ROS), such as singlet oxygen and peroxynitrite, and inhibit lipid peroxidation.

HY-146273

Xanthine oxidase-IN-7	Xanthine Oxidase	Metabolic Disease
Xanthine oxidase-IN-7 (compound1h) is a potent andorally active *XO (xanthine* oxidase) inhibitor with an IC₅₀** of 0.36 µM. Xanthine oxidase-IN-7 effectively reduces serum uric acid levels. Xanthine oxidase-IN-7 has the potential for the research of hyperuricemia and gout .

HY-B1514R

Allantoic acid (Standard)	Reference Standards Endogenous Metabolite	Others
Anagrelide (hydrochloride) (Standard) is the analytical standard of Anagrelide (hydrochloride). This product is intended for research and analytical applications. Anagrelide hydrochloride (BL4162A) is a potent inhibitor of phosphodiesterase type III (PDE3) (IC50=36 nM). Anagrelide hydrochloride, an imidazoquinazoline derivative, acts as an inhibitor of platelet aggregation. Anagrelide hydrochloride inhibits bone marrow megakaryocytopoiesis. Anagrelide hydrochloride decreases gastrointestinal stromal tumor (GIST) cell proliferation and promotes their apoptosis in vitro. Anagrelide hydrochloride is a platelet-lowering agent and plays in the antithrombopoietic action .

HY-W017386S

3-Methyl-2-oxovaleric acid-d8 sodium	Isotope-Labeled Compounds Endogenous Metabolite	Metabolic Disease
3-Methyl-2-oxovaleric acid-d₈ sodium is the deuterium labeled 3-Methyl-2-oxovaleric acid. 3-Methyl-2-oxovaleric acid is a degradation product from Isoleucine. 3-Methyl-2-oxovaleric acid is a biomarker of mustard airway diseases (MADs) and uric acid stone .

HY-169089

RP-182-PEG3-K(palmitic acid)-NH2	Drug Derivative	Cancer
RP-182-PEG3-K palmitic acid-NH2 (Compound 1a) is a fatty acid derivative of the immunomodulatory peptide RP-182. RP-182-PEG3-K palmitic acid-NH2 inhibits CD206 ^high M2-like macrophage (IC₅₀ of 3.2 μM) and induces phagocytosis. RP-182-PEG3-K palmitic acid-NH2 exhibits antitumor efficacy in mouse B16 melanoma allografts .

HY-P2921A

Uricase, Bacillus fastidious Uox, Bacillus fastidious	Endogenous Metabolite	Metabolic Disease Inflammation/Immunology
Uricase, Bacillus fastidious (Uox, Bacillus fastidious) is a uricase (urate oxidase) derived from Bacillus fastidious. Uricase, Bacillus fastidious converts uric acid into allantoin. The absence of Uricase in mammals causes kidney diseases resulting from uric acid accumulation. Uricase, Bacillus fastidious can be used for research on chronic refractory gout and hyperuricemia .

HY-P2921B

Uricase, Arthrobacter globiformis Uox, Arthrobacter globiformis	Endogenous Metabolite	Metabolic Disease Inflammation/Immunology
Uricase, Arthrobacter globiformis (Uox, Arthrobacter globiformis) is a uricase (urate oxidase) derived from Arthrobacter globiformis. Uricase, Arthrobacter globiformis converts uric acid into allantoin. The absence of Uricase in mammals causes kidney diseases resulting from uric acid accumulation. Uricase, Arthrobacter globiformis can be used for research on chronic refractory gout and hyperuricemia .

HY-W001542R

5-Hydroxyoxindole (Standard)	Reference Standards Reactive Oxygen Species (ROS)	Neurological Disease Metabolic Disease Cancer
5-Hydroxyoxindole is a structural analog of uric acid for its antioxidant. 5-Hydroxyoxindole has DPPH radical scavenging activities and lipid peroxidation-inhibitory activities. 5-Hydroxyoxindole is a product of partial metabolism of tryptophan involving conversion in the gut lumen of tryptophan to indole through the action of bacterial tryptophanase and tryptophan synthase. 5-Hydroxyoxindole is one of the main molecules responsible for the neurological symptoms of hepatic encephalopathy in rats. 5-Hydroxyoxindole can be used for the research of oxidative stress-mediated disorders .

HY-151173

XO/COX/LOX-IN-1	Xanthine Oxidase Lipoxygenase COX	Metabolic Disease Inflammation/Immunology
XO/COX/LOX-IN-1 is a XO/COX/LOX inhibitor with an IC₅₀ of 3.2 μM against rat XO, 10.83 μM against 5-LOX, 12.67 μM against COX-1, and 8.31 μM against COX-2. XO/COX/LOX-IN-1 binds to the active sites of XO, 5-LOX, COX-1 and COX-2, thereby blocking enzyme activities associated with uric acid, leukotriene, prostaglandin synthesis and inflammatory pathways. XO/COX/LOX-IN-1 can be used in the research of hyperuricemia and inflammation .

HY-P11233

Acmopatide	GLP Receptor	Metabolic Disease
Acmopatide (Compound E-153) is a dual-acting GIP/GLP-1 receptor agonist. Acmopatide is used in anti-diabetic research .

HY-172778

HNW005	NOD-like Receptor (NLR) URAT1	Metabolic Disease Inflammation/Immunology
HNW005 is a dual inhibitor of NLRP3 inflammasome and urate transporter 1 (URAT1). It has a K_D value of 204.6 nM and an IC₅₀ of 1.7 μM for inhibiting NLRP3 inflammasome activation, and an IC₅₀ of 6.4 μM for inhibiting uric acid transmembrane transport. When administered at a dose of 2 mg/kg in vivo, HNW005 can achieve a uric acid reduction rate of 64.8%. It can exert anti - inflammatory, analgesic, and uric acid - lowering activities by inhibiting the activation of NLRP3 inflammasome and uric acid transmembrane transport. HNW005 can be used in the research of gouty arthritis .

HY-W075315

Xanthine oxidoreductase-IN-6	MOFs Xanthine Oxidase Cytochrome P450	Metabolic Disease
Xanthine oxidoreductase-IN-6 (Compound 4) is an orally active xanthine oxidoreductase (XOR) inhibitor with an IC₅₀ of 170 nM. Xanthine oxidoreductase-IN-6 can block the final step of uric acid biosynthesis and lower serum uric acid levels. Xanthine oxidoreductase-IN-6 also shows Cytochrome P450 3A4 (CYP3A4) inhibitory activity. Xanthine oxidoreductase-IN-6 can be used for the research of hyperuricemia .

HY-175303

Xanthine oxidase-IN-17	Xanthine Oxidase	Metabolic Disease
Xanthine oxidase-IN-17 is a potent xanthine oxidase (XOD) inhibitor with an IC₅₀ of 298 nM and a K_i of 167 nM. Xanthine oxidase-IN-17 decreases the formation of O_₂ ^⁻ radical by inhibiting the catalytic activity of XOD to diminish the production of uric acid. Xanthine oxidase-IN-17 shows no cytotoxicity in AML-12 hepatocytes, while suppressing uric acid production. Xanthine oxidase-IN-17 can be used for the studies of hyperuricemia and subsequently to gout .

HY-158056

URAT1/GLUT9-IN-1	GLUT URAT1	Metabolic Disease
URAT1/GLUT9-IN-1 (compound 29) can inhibit both uric acid transporter 1 (URAT1) (IC₅₀=2.01 μM) and glucose transporter 9 (GLUT9) (IC₅₀=18.21 μM). URAT1/GLUT9-IN-1 exhibits favorable pharmacokinetic properties and oral bioavailability. URAT1/GLUT9-IN-1 can be uesd for gout and hyperuricemia research .

Cat. No.	Product Name	Type

HY-15933

TOPS 1 Publications Verification	Biochemical Assay Reagents
TOPS is a chromogenic substrate. TOPS undergoes an oxidative coupling reaction with 4-aminoantipyrine in the presence of H₂O₂ and nanocrystalline cobalt selenide. TOPS is used in studies related to uric acid detection .

HY-W017386

3-Methyl-2-oxovaleric acid sodium 3 Publications Verification	Biochemical Assay Reagents
3-Methyl-2-oxovaleric acid sodium is a degradation product from Isoleucine. 3-Methyl-2-oxovaleric acid sodium is a biomarker of mustard airway diseases (MADs) and uric acid stone .

Cat. No.	Product Name	Target	Research Area

HY-P0014

Liraglutide Maximum Cited Publications 38 Publications Verification	GCGR GLP Receptor	Metabolic Disease Cancer
Liraglutide is a glucagon-like peptide-1 (GLP-1) receptor agonist used clinically to treat type 2 diabetes mellitus.

HY-P3462

Cagrilintide 3 Publications Verification	CGRP Receptor	Metabolic Disease
Cagrilintide is an investigational novel long-acting acylated amylin analogue, acts as nonselective amylin receptors (AMYR) and calcitonin G protein-coupled receptor (CTR) agonist. Cagrilintide induces significant weight loss and reduces food intake. Cagrilintide has the potential for the research of obesity .

HY-P3462A

Cagrilintide acetate 3 Publications Verification	CGRP Receptor	Metabolic Disease
Cagrilintide acetate is a non-selective AMYR/CTR agonist and long-acting acylated amylase analogue. Cagrilintide acetate causes a reduction in food intake and significant weight loss in a dose-dependent manner. Cagrilintide acetate can be used in obesity studies .

HY-P10272

Rusfertide PTG-300	Ferroportin	Others
Rusfertide is a peptide mimetic of natural hepcidin, which targets and degrades ferroportin, reduces serum iron and transferrin-saturation, and thus regulates the production of red blood cells. Rusfertide ameliorates the polycythemia vera, β-thalassemia and hereditary hemochromatosis .

HY-P2231

Cotadutide 1 Publications Verification MEDI0382	GCGR	Metabolic Disease
Cotadutide (MEDI0382) is a potent dual agonist of glucagon-like peptide-1 (GLP-1) and GCGR with EC₅₀ values of 6.9 pM and 10.2 pM, respectively. Cotadutide exhibits ability to facilitate both weight loss and glycaemic control, and alleviate fibrosis. Cotadutide can be used in the research of obesity and type 2 diabetes (T2D) .

HY-P2231A

Cotadutide acetate 1 Publications Verification MEDI0382 acetate	GCGR	Metabolic Disease
Cotadutide (MEDI0382) acetate is a potent dual agonist of glucagon-like peptide-1 (GLP-1) and GCGR with EC₅₀ values of 6.9 pM and 10.2 pM, respectively. Cotadutide acetate exhibits ability to facilitate both weight loss and glycaemic control, and alleviate fibrosis. Cotadutide acetate can be used in the research of obesity and type 2 diabetes (T2D) .

HY-P3291

Dapiglutide 1 Publications Verification ZP7570	GCGR	Metabolic Disease
Dapiglutide (ZP7570) is a long-acting glucagon-like peptide-1 receptor 1R (GLP-1R)/Glucagon-like peptide-2 receptor (GLP-2R) dual agonist. Dapiglutide alleviates intestinal dysfunction in a mouse short bowel model and has anti-obesity effects .

HY-P10218

MANS peptide 1 Publications Verification	MARCKS PKC	Inflammation/Immunology Cancer
MANS peptide is an inhibitor for myristoylated alanine-rich C kinase substrate (MARCKS), which competes with MARCKS in cells for membrane binding, and thus inhibits the stimulation of mucin secretion and tumor metastasis .

HY-P0014S1

Liraglutide-13C5,15N tetraTFA	Isotope-Labeled Compounds GLP Receptor GCGR	Others
Liraglutide- ¹³C₆, ¹⁵ tetraTFA is the ¹³C and ¹⁵N labeled Liraglutide (HY-P0014) . Liraglutide is a glucagon-like peptide-1 (GLP-1) receptor agonist used for the study of type 2 diabetes mellitus .

HY-P10271

RG7697 NNC0090-2746; MAR709; RO6811135	GLP Receptor	Metabolic Disease
RG7697 is a dual agonist for glucagon-like peptide receptor (GLP Receptor) and glucosedependent insulinotropic polypeptide receptor (GIPR), with EC₅₀ of 5 and 3 pM, respectively. RG7697 exhibits antihyperglycemic property .

HY-P10031

SAR441255	GLP Receptor GCGR	Metabolic Disease
SAR441255 is a GLP-1R/GCGR/GIPR agonist, with human EC₅₀ values of 1.03 pM, 1.01 pM, and 0.73 pM, respectively. SAR441255 stimulates receptor activity and drives cAMP accumulation. SAR441255 can be used for the research of type 2 diabetes, obesity .

HY-W011258

H-Tyr-Phe-OH L-Tyrosyl-L-phenylalanine	Xanthine Oxidase Angiotensin-converting Enzyme (ACE)	Inflammation/Immunology Cancer
H-Tyr-Phe-OH (L-Tyrosyl-L-phenylalanine) is an orally active inhibitor of Angiotensin converting enzyme (ACE), with an inhibiton rate of 48% at 50 μM. H-Tyr-Phe-OH can be used as an biomarker for differentiating benign thyroid nodules (BTN) from thyroid cancer (TC). H-Tyr-Phe-OH exhibits xanthine oxidase inhibition (uric acid lowering) activity and serves as regulator in IL-8 production in neutrophil-like cells .

HY-P10218A

MANS peptide TFA 1 Publications Verification	MARCKS PKC	Inflammation/Immunology Cancer
MANS peptide TFA is the TFA salt form of MANS peptide (HY-P10218). MANS peptide TFA is an inhibitor for myristoylated alanine-rich C kinase substrate (MARCKS), which competes with MARCKS in cells for membrane binding, and thus inhibits the stimulation of mucin secretion and tumor metastasis .

HY-P0014B

Liraglutide TFA Maximum Cited Publications 38 Publications Verification	GLP Receptor	Metabolic Disease
Liraglutide (TFA) is an agonist of glucagon-like peptide 1 receptor (GLP-1). Liraglutide (TFA) can activate GLP-1, leading to the release of insulin in the presence of increased glucose concentration. Liraglutide (TFA) also reduces glucagon secretion in a glucose-dependent manner. Liraglutide (TFA) can be studied in research on type 2 diabetes .

HY-P3143

BMSpep-57	PD-1/PD-L1	Cancer
BMSpep-57 is a potent and competitive macrocyclic peptide inhibitor of PD-1/PD-L1 interaction with an IC₅₀ of 7.68 nM. BMSpep-57 binds to PD-L1 with K_ds of 19 nM and 19.88 nM in MST and SPR assays, respectively. BMSpep-57 facilitates T cell function by in creasing IL-2 production in PBMCs .

HY-P11273

Urcosimod OK 101	Chemerin Receptor	Neurological Disease Inflammation/Immunology
Urcosimod (OK 101) is a lipid-coupled chemokine peptide, a ChemR23 G protein-coupled receptor agonist, which has been shown to have anti-inflammatory and analgesic activities. Urcosimod can be used for dry eye research .

HY-153476A

GIP/GLP-1 dual receptor agonist-1 sodium	GLP Receptor GCGR	Inflammation/Immunology
GIP/GLP-1 dual receptor agonist-1 sodium is a GIP/GLP-1 dual receptor agonist. GIP/GLP-1 dual receptor agonist-1 sodium is used in the research of metabolic disorders and fatty liver diseases, including non-alcoholic steatohepatitis (NASH) and non-alcoholic fatty liver disease (NAFLD) .

HY-153476

GIP/GLP-1 dual receptor agonist-1	GCGR GLP Receptor	Inflammation/Immunology
GIP/GLP-1 dual receptor agonist-1 is a GIP/GLP-1 dual receptor agonist. GIP/GLP-1 dual receptor agonist-1 is used in the research of metabolic disorders and fatty liver diseases, including non-alcoholic steatohepatitis (NASH) and non-alcoholic fatty liver disease (NAFLD) .

HY-P11290

MC4-NN2-0453	Melanocortin Receptor	Metabolic Disease
MC4-NN2-0453, a α-MSH analog, is a selective MC4R agonist. MC4-NN2-0453 can be used for obesity research .

HY-P10341

ZP3022	GCGR	Metabolic Disease
ZP3022 is a dual agonist of glucagon-like peptide-1 (GLP-1) and gastrin that has the ability to sustainably improve glycemic control. Additionally, ZP3022 can effectively increase β-cell mass, promote β-cell proliferation, and enhance the function of pancreatic islets. ZP3022 can be used in anti-diabetic research .

HY-169089

RP-182-PEG3-K(palmitic acid)-NH2	Drug Derivative	Cancer
RP-182-PEG3-K palmitic acid-NH2 (Compound 1a) is a fatty acid derivative of the immunomodulatory peptide RP-182. RP-182-PEG3-K palmitic acid-NH2 inhibits CD206 ^high M2-like macrophage (IC₅₀ of 3.2 μM) and induces phagocytosis. RP-182-PEG3-K palmitic acid-NH2 exhibits antitumor efficacy in mouse B16 melanoma allografts .

HY-P10563

Noraramtide BHV-1100	CD38	Cancer
Noraramtide (BHV-1100) is an antibody recruitment molecule. Noraramtide can specifically bind to CD38 molecules to recruit natural killer (NK) cells. Noraramtide enhances the ability of NK cells to kill tumor cells through antibody-dependent cellular cytotoxicity (ADCC). This mechanism allows NK cells to more effectively recognize and eliminate tumor cells while avoiding mutual killing between NK cells. Noraramtide can be used for the study of autologous cancer immunity .

HY-P11233

Acmopatide	GLP Receptor	Metabolic Disease
Acmopatide (Compound E-153) is a dual-acting GIP/GLP-1 receptor agonist. Acmopatide is used in anti-diabetic research .

HY-P0014AS

Liraglutide-d8 tetraTFA	Isotope-Labeled Compounds GLP Receptor	Metabolic Disease
Liraglutide-d₈ tetraTFA is deuterium labeled Liraglutide (HY-P0014). Liraglutide is a glucagon-like peptide-1 (GLP-1) receptor agonist used for the study of type 2 diabetes mellitus .

HY-P10031A

SAR441255 TFA	GLP Receptor GCGR	Metabolic Disease
SAR441255 TFA is a GLP-1R/GCGR/GIPR agonist, with human EC₅₀ values of 1.03 pM, 1.01 pM, and 0.73 pM, respectively. SAR441255 TFA stimulates receptor activity and drives cAMP accumulation. SAR441255 TFA can be used for the research of type 2 diabetes, obesity .

HY-169089A

RP-182-PEG3-K(palmitic acid)-NH2 TFA	Drug Derivative	Cancer
RP-182-PEG3-K(palmitic acid)-NH2 (Compound 1a) TFA is a fatty acid derivative of the immunomodulatory peptide RP-182. RP-182-PEG3-K(palmitic acid)-NH2 TFA inhibits CD206 ^high M2-like macrophage (IC₅₀ of 3.2 μM) and induces phagocytosis. RP-182-PEG3-K(palmitic acid)-NH2 TFA exhibits antitumor efficacy in mouse B16 melanoma allografts .

HY-P0014A

Liraglutide acetate	GLP Receptor	Metabolic Disease
Liraglutide acetate is the acetate form of Liraglutide (HY-P0014), a glucagon-like peptide-1 (GLP-1) receptor agonist studied in type 2 diabetes .

HY-P10318

SHR-2042	GLP Receptor	Endocrinology
SHR-2042 is a selective agonist of the GLP-1 receptor.SHR-2042 improves glycemic control by activating the GLP-1 receptor, enhancing insulin secretion and inhibiting glucagon secretion. SHR-2042 combined with sodium N-(8-[2-hydroxybenzoyl] amino) caprylate (SNAC) promotes monomerization through the formation of micelles and improves oral absorption efficiency .

HY-P1614

ZEP-3	Reactive Oxygen Species (ROS)	Metabolic Disease Inflammation/Immunology
ZEP-3 is a tetrapeptide derivative with anti-aging activity for the skin. ZEP-3 can inhibit ROS production and alleviate oxidative stress .

HY-P0041A

F992 TFA	Vasopressin Receptor	Neurological Disease
F992 TFA is an antidiuretic peptide and vasopressin (antidiuretic hormone) analogue .

HY-P0014S2

Liraglutide-13C6,15N TFA	Isotope-Labeled Compounds	Others
Liraglutide- ¹³C₆, ¹⁵ TFA is the ¹³C and ¹⁵N labeledLiraglutide(HY-P0014). Liraglutide is a glucagon-like peptide-1 (GLP-1) receptor agonist used for the study of type 2 diabetes mellitus .

HY-P3143A

BMSpep-57 hydrochloride	PD-1/PD-L1	Cancer
BMSpep-57 hydrochloride is a potent and competitive macrocyclic peptide inhibitor of PD-1/PD-L1 interaction with an IC₅₀ of 7.68 nM. BMSpep-57 hydrochloride binds to PD-L1 with K_ds of 19 nM and 19.88 nM in MST and SPR assays, respectively. BMSpep-57 hydrochloride facilitates T cell function by in creasing IL-2 production in PBMCs .

HY-113560

Plipastatin B1	Antibiotic Fungal Phospholipase	Infection
Plipastatin B1 is a lipopeptide antibiotic, an inhibitor of phospholipase A₂ (PLA2), which has antifungal activity .

HY-P1162

(d(CH2)51,Tyr(Me)2,Arg8)-Vasopressin SKF 100273	Vasopressin Receptor	Metabolic Disease
(d(CH2)51,Tyr(Me)2,Arg8)-Vasopressin (SKF 100273) is a vasopressin V1 receptor selective antagonist .

HY-P10910

Vensemaglutide	GLP Receptor	Metabolic Disease
Vensemaglutide is the agonist for glucagon-like peptide 1 (GLP-1) receptor. Vensemaglutide can be used in research of diabetes or other metabolic disorders .

HY-P11243

EphA4 agonist compound 23	Ephrin Receptor	Neurological Disease
EphA4 agonist compound 23 is a novel EphA4 agonist peptide mimic. EphA4 agonist compound 23 exhibits high affinity, high selectivity, and significant receptor activation ability. EphA4 agonist compound 23 is commonly used in the study of neurodegenerative diseases .

HY-P10876

mcK6A1	Amyloid-β	Neurological Disease
mcK6A1 is an inhibitor for the aggregation of amyloid-β (Aβ), that selectively binds to the 16KLVFFA21 segment of Aβ42, forms an extended β-folded structure, and inhibits the formation of Aβ42 oligomers. mcK6A1 can be used in research of Alzheimer's disease and other amyloid-related diseases .

HY-P10869

dCNP 1 Publications Verification	Natriuretic Peptide Receptor (NPR)	Inflammation/Immunology Cancer
dCNP binds to NPR-B/C receptor, activates cGMP signaling pathway, and regulates vascular function. dCNP exhibits anti-hypoxia property through downregulation of hypoxia-related genes expressions like HIF1α and HIF2α. dCNP inhibits the induction of tumor stroma and exhibits anti-fibrosis activity. dCNP upregulates CTLs, NK cells, and conventional type 1 dendritic cells in tumors, and activates immune responses .

HY-P4837

Ac-Lys-D-Ala-D-lactic acid	Peptides	Others
Ac-Lys-D-Ala-D-lactic acid is a polypeptide that can be found by peptide screening. Peptide screening is a research tool that pools active peptides primarily by immunoassay. Peptide screening can be used for protein interaction, functional analysis, epitope screening, especially in the field of agent research and development .

HY-P10200

CP7-FP13-2	Bacterial	Infection
CP7-FP13-2 is a peptide with antivirulence factor and antibacterial activity. CP7-FP13-2 inhibits the formation of Staphylococcus aureus biofilm and has good antibacterial efficacy in mice .

HY-P0041

F992	Vasopressin Receptor	Neurological Disease
F992 is an antidiuretic peptide and vasopressin (antidiuretic hormone) analogue .

HY-P5161

FC382K10W15	GLP Receptor GCGR	Metabolic Disease
FC382K10W15 is a glucagon analogue and GLP-1R/GCGR agonist. FC382K10W15 can be used in type 2 diabetes research .

HY-109166

Amdakefalin	Opioid Receptor	Neurological Disease
Amdakefalin is a μ and δ opioid receptors agonist with analgesic effects .

HY-P5161A

FC382K10W15 TFA	GLP Receptor GCGR	Metabolic Disease
FC382K10W15 TFA is a glucagon analogue and GLP-1R/GCGR agonist. FC382K10W15 TFA can be used in type 2 diabetes research .

HY-P11279

TC2	GLP Receptor GCGR Neuropeptide Y Receptor	Metabolic Disease
TC2 is an efficient GIPR-preferring monomeric quadruple agonist that can respectively activate GIPR, GLP-1R, GcgR, and Y2R with IC₅₀ values of 0.47, 2.1, 30, and 55 nM respectively. TC2 exhibits a significant GLP-1R preference, with a significant reduction in β-inhibitory protein 2 (βArr2) recruitment, while maintaining a strong cAMP signal. TC2 can be used for research on obesity and diabetes .

HY-P10381

palm11-TTDS-PrRP31	Peptides	Others
palm11-TTDS-PrRP31 is a strong agonist of GPR10 (EC₅₀: 84 pM). palm11-TTDS-PrRP31 has long-lasting anorexigenic effects .

HY-P2595

SKF 103784	Endogenous Metabolite	Cardiovascular Disease
SKF 103784 is an vasopressin antagonist with activity against vasopressin. SKF 103784 inhibits the physiological response caused by antidiuretic and is therefore used to study biological processes related to water and salt balance. SKF 103784 can also be used to explore pathological mechanisms related to cardiovascular diseases and endocrine dysfunction .

HY-P10881

Ganipatide	Peptide-Drug Conjugates (PDCs)	Metabolic Disease
Ganipatide is a 1-31-Glucose-dependent insulinotropic polypeptide. Ganipatide is promising for research of diabetes .

HY-P11759

Myr-transportan-Cys	Drug Derivative	Cancer
Myr-transportan-Cys is a derivative of the cell-penetrating peptide Transportan (HY-P1732), and its conjugated myristoyl group (Myr) enhances the interaction between the peptide and cell membranes. Myr-transportan-Cys integrates three key delivery functions: nucleic acid condensation, cell penetration, and endosomal escape. Myr-transportan-Cys can form immunostimulatory tandem peptide nanocomplexes (iTPNCs) for encapsulating and delivering immunostimulatory oligonucleotide cargos to tumors .

HY-N17580

Lyciumin D	Renin	Cardiovascular Disease
Lyciumin D acts as an angiotensin-converting enzyme inhibitor and renin inhibitor. Lyciumin D can be used for the research of hypertension .

Cat. No.	Product Name	Category	Target	Chemical Structure

HY-B2130

Uric acid Maximum Cited Publications 21 Publications Verification	Structural Classification Classification of Application Fields Endocrine diseases Endogenous metabolite Human Gut Microbiota Metabolites Microorganisms Ketones, Aldehydes, Acids Disease markers Nervous System Disorder Inflammation/Immunology Disease Research Fields Cancer Source Classification	Environmental Pollutants Endogenous Metabolite Reactive Oxygen Species (ROS)
Uric acid, scavenger of oxygen radical, is a very important antioxidant that help maintains the stability of blood pressure and antioxidant stress. Uric acid can remove reactive oxygen species (ROS) such as singlet oxygen and peroxynitrite, inhibiting lipid peroxidation .

HY-B2130A

Uric acid sodium Maximum Cited Publications 21 Publications Verification Monosodium urate	Natural Products Classification of Application Fields Metabolic Disease Endogenous metabolite Disease Research Fields Source Classification	Reactive Oxygen Species (ROS) Endogenous Metabolite
Uric acid sodium (Monosodium urate), scavenger of oxygen radical, is a very important antioxidant that help maintains the stability of blood pressure and antioxidant stress. Uric acid sodium can remove reactive oxygen species (ROS) such as singlet oxygen and peroxynitrite, inhibiting lipid peroxidation .

HY-113063

3-Methyl-2-oxovaleric acid 3 Publications Verification	Human Gut Microbiota Metabolites Microorganisms Classification of Application Fields Ketones, Aldehydes, Acids Other Diseases Endogenous metabolite Disease Research Fields Source Classification	Endogenous Metabolite
3-Methyl-2-oxovaleric acid is a degradation product from Isoleucine. 3-Methyl-2-oxovaleric acid is a biomarker of mustard airway diseases (MADs) and uric acid stone .

HY-108844

Rasburicase	Natural Products Classification of Application Fields Metabolic Disease Endogenous metabolite Disease Research Fields Source Classification	Xanthine Oxidase
Rasburicase is a recombinant form of urate oxidase that works by catalyzing the oxidation of uric acid to allantoin, which has a higher solubility. Rasburicase specifically degrades uric acid, rapidly lowers blood uric acid levels, and improves inflammation and kidney damage caused by uric acid crystal deposition. Rasburicase can effectively lower uric acid and prevent uric acid nephropathy, and is used in the study of severe hyperuricemia associated with tumor lysis syndrome (TLS) and refractory gout .

HY-W012658

2-Methylacetophenone O-Methylacetophenone	Structural Classification Classification of Application Fields Ketones, Aldehydes, Acids Metabolic Disease Endogenous metabolite Disease Research Fields Source Classification	Xanthine Oxidase
2-Methylacetophenone (O-Methylacetophenone), acetophenone derivative and acaricide, is a xanthine dehydrogenase (XDH) inhibitor. 2-Methylacetophenone competitively binds to the XDH active site, blocking the pathway for xanthine to be converted to uric acid. 2-Methylacetophenone can be used for the study of hyperuricemia and house dust .

HY-B1514

Allantoic acid 1 Publications Verification	Human Gut Microbiota Metabolites Microorganisms Classification of Application Fields Ketones, Aldehydes, Acids Other Diseases Endogenous metabolite Disease Research Fields Source Classification	Endogenous Metabolite
Allantoic acid is a degradative product of uric acid and associated with purine metabolism .

HY-126061

1,7-Dimethyluric acid	Structural Classification Natural Products Human Gut Microbiota Metabolites Immune System Disorder Neurological Disease Classification of Application Fields Disease markers Endogenous metabolite Disease Research Fields Source Classification	Biochemical Assay Reagents Drug Metabolite
1,7-Dimethyluric acid is an N-methylated uric acid and purine derivative, as well as a caffeine metabolite. When 1,7-Dimethyluric acid is acted upon by peroxidase in the presence of H₂O₂, it follows the same oxidation pathway to generate a UV-absorbing intermediate, which decays via first-order kinetics. 1,7-Dimethyluric acid can adsorb onto pyrolytic graphite electrodes, but not onto glassy carbon electrodes or platinum electrodes. The N-methylation modification of its pyrimidine ring prevents ring contraction of the diol intermediate, and no NMR evidence of O-alkylation is observed during propylation under the test conditions .

HY-W001542

5-Hydroxyoxindole	Alkaloids Monophenols Neurological Disease Classification of Application Fields Rubiaceae Phenols Haldina cordifolia (Roxb.) Ridsd. Metabolic Disease Plants Disease Research Fields Indole Alkaloids Source Classification	Reactive Oxygen Species (ROS)
5-Hydroxyoxindole is a structural analog of uric acid for its antioxidant. 5-Hydroxyoxindole has DPPH radical scavenging activities and lipid peroxidation-inhibitory activities. 5-Hydroxyoxindole is a product of partial metabolism of tryptophan involving conversion in the gut lumen of tryptophan to indole through the action of bacterial tryptophanase and tryptophan synthase. 5-Hydroxyoxindole is one of the main molecules responsible for the neurological symptoms of hepatic encephalopathy in rats. 5-Hydroxyoxindole can be used for the research of oxidative stress-mediated disorders .

HY-B2130R

Uric acid (Standard)	Structural Classification Human Gut Microbiota Metabolites Microorganisms Ketones, Aldehydes, Acids Disease markers Endocrine diseases Nervous System Disorder Endogenous metabolite Cancer Source Classification	Reference Standards Reactive Oxygen Species (ROS) Endogenous Metabolite
Uric acid (Standard) is the analytical standard of Uric acid. This product is intended for research and analytical applications. Uric acid, scavenger of oxygen radical, is a very important antioxidant that help maintains the stability of blood pressure and antioxidant stress. Uric acid can remove reactive oxygen species (ROS) such as singlet oxygen and peroxynitrite, inhibiting lipid peroxidation .

HY-113063R

3-Methyl-2-oxovaleric acid (Standard)	Structural Classification Human Gut Microbiota Metabolites Microorganisms Ketones, Aldehydes, Acids Endogenous metabolite Source Classification	Reference Standards Endogenous Metabolite
3-Methyl-2-oxovaleric acid (Standard) is the analytical standard of 3-Methyl-2-oxovaleric acid (HY-113063). This product is intended for research and analytical applications. 3-Methyl-2-oxovaleric acid is a degradation product from Isoleucine. 3-Methyl-2-oxovaleric acid is a biomarker of mustard airway diseases (MADs) and uric acid stone.

HY-W017389R

Xanthine (Standard)	Structural Classification Natural Products Microorganisms Disease markers Endocrine diseases Nervous System Disorder Camellia sinensis (L.) O. Ktze. Plants Endogenous metabolite Source Classification Theaceae	Reference Standards Endogenous Metabolite
Xanthine (Standard) is the analytical standard of Xanthine. This product is intended for research and analytical applications. Xanthine, a plant alkaloid found in tea, coffee, and cocoa, is a mild stimulant of the central nervous system. Xanthine also acts as an intermediate product on the pathway of purine degradation . In Vitro: A number of stimulants are derived from Xanthine including caffeine and theobromine. Xanthine is a product on the pathway of purine degradation. Xanthine is subsequently converted to uric acid by the action of the Xanthine oxidase enzyme.

HY-135319

Strictinin	Structural Classification Phenols Polyphenols Camellia sinensis (L.) O. Ktze. Plants Source Classification Theaceae	Bacterial Antibiotic ERK JNK NF-κB ROR Apoptosis Caspase GSK-3 Akt PI3K
Strictinin is an orally active phenolic compound. Strictinin reduces xanthine oxidase activity, uric acid production, and the activation of ERK1/2, JNK, NF-κB, and NLRP3 inflammasome components in hepatocytes treated with Xanthine (HY-W017389). Strictinin decreases elevated serum uric acid levels and enhanced xanthine oxidase activity in mice treated with potassium oxonate. Strictinin acts as a ROR1 inhibitor and exhibits anticancer activity against highly aggressive non-androgen-dependent prostate cancer. Strictinin induces cancer cell apoptosis (apoptosis), arrests cell cycle, and inhibits cancer cell migration, invasion, and epithelial-mesenchymal transition. Strictinin modulates gut microbiota, inhibits bacterial growth and biofilm formation, accelerates small intestinal transit, and blocks viral entry and replication. Strictinin can be used in research related to hyperuricemia, androgen receptor-negative non-androgen-dependent prostate cancer, triple-negative breast cancer, bacterial infections, constipation, coronavirus infections, dental caries, and infections caused by influenza A, influenza B, and human parainfluenza virus type 1 .

HY-B1514R

Allantoic acid (Standard)	Structural Classification Human Gut Microbiota Metabolites Microorganisms Ketones, Aldehydes, Acids Endogenous metabolite Source Classification	Reference Standards Endogenous Metabolite
Anagrelide (hydrochloride) (Standard) is the analytical standard of Anagrelide (hydrochloride). This product is intended for research and analytical applications. Anagrelide hydrochloride (BL4162A) is a potent inhibitor of phosphodiesterase type III (PDE3) (IC50=36 nM). Anagrelide hydrochloride, an imidazoquinazoline derivative, acts as an inhibitor of platelet aggregation. Anagrelide hydrochloride inhibits bone marrow megakaryocytopoiesis. Anagrelide hydrochloride decreases gastrointestinal stromal tumor (GIST) cell proliferation and promotes their apoptosis in vitro. Anagrelide hydrochloride is a platelet-lowering agent and plays in the antithrombopoietic action .

HY-Y0106

2,6-Dihydroxyacetophenone	Classification of Application Fields Ketones, Aldehydes, Acids Phenols Polyphenols Metabolic Disease Endogenous metabolite Disease Research Fields Source Classification	mTOR Xanthine Oxidase Apoptosis
2,6-Dihydroxyacetophenone, a polyphenolic derivative of Acetophenone (HY-Y0989), is an orally active mTOR inhibitor. 2,6-Dihydroxyacetophenone shows antioxidant activity. 2,6-Dihydroxyacetophenone inhibits cell growth and proliferation in CRC cells. 2,6-Dihydroxyacetophenone arrests at G0/G1 phase of cell cycle, induces apoptosis and suppresses cell migration in CRC cells. 2,6-Dihydroxyacetophenone inhibits xanthine oxidase (XOD) with an IC₅₀ of 1.24 mM. 2,6-dihydroxyacetophenone improves uric acid metabolism in hyperuricemia mice, reduces plasma cholesterol in hypercholesterolemic rats, and inhibits lipid accumulation in HFD-induced obese mice. 2,6-Dihydroxyacetophenone can be used for the study of colorectal cancer (CRC), hyperuricemia and hypercholesterolemia .

HY-W001542R

5-Hydroxyoxindole (Standard)	Alkaloids Structural Classification Monophenols Rubiaceae Phenols Haldina cordifolia (Roxb.) Ridsd. Plants Indole Alkaloids Source Classification	Reference Standards Reactive Oxygen Species (ROS)
5-Hydroxyoxindole is a structural analog of uric acid for its antioxidant. 5-Hydroxyoxindole has DPPH radical scavenging activities and lipid peroxidation-inhibitory activities. 5-Hydroxyoxindole is a product of partial metabolism of tryptophan involving conversion in the gut lumen of tryptophan to indole through the action of bacterial tryptophanase and tryptophan synthase. 5-Hydroxyoxindole is one of the main molecules responsible for the neurological symptoms of hepatic encephalopathy in rats. 5-Hydroxyoxindole can be used for the research of oxidative stress-mediated disorders .

HY-B2130AR

Uric acid sodium (Standard) Monosodium urate (Standard)	Structural Classification Natural Products Endogenous metabolite Source Classification	Reactive Oxygen Species (ROS) Endogenous Metabolite Reference Standards
Uric acid (sodium) (Standard) is the analytical standard of Uric acid (sodium). This product is intended for research and analytical applications. Uric acid sodium (Monosodium urate), scavenger of oxygen radical, is a very important antioxidant that help maintains the stability of blood pressure and antioxidant stress. Uric acid sodium can remove reactive oxygen species (ROS) such as singlet oxygen and peroxynitrite, inhibiting lipid peroxidation .

HY-N10433

Xanthine oxidase-IN-9 Icarisids E	Flavonoids Juglandaceae Cyclocarya paliurus (Batal.) Iljinsk. Plants Source Classification	Xanthine Oxidase
Xanthine oxidase-IN-9 (Icarisids E) (Compound 2) is a potent xanthine oxidase (XOD) inhibitor with an IC₅₀ of 31.81 μM .

HY-119596

Eupatoriochromene	Monophenols Anthyllis vulneraria L. Phenols Plants Compositae Source Classification	Xanthine Oxidase
Eupatoriochromene is a chromene and has inhibitory activity against xanthine oxidase (XO) .

HY-180671

Uric acid riboside	Structural Classification Animals Ketones, Aldehydes, Acids Endogenous metabolite Source Classification	Drug Metabolite
Uric acid riboside is a minor metabolite of Uric acid (HY-B2130) in butterfly wings .

HY-W012658R

2-Methylacetophenone (Standard) O-Methylacetophenone (Standard)	Structural Classification Ketones, Aldehydes, Acids Endogenous metabolite Source Classification	Reference Standards Xanthine Oxidase
2-Methylacetophenone (O-Methylacetophenone) (Standard) is the analytical standard of 2-Methylacetophenone (HY-W012658). This product is intended for research and analytical applications. 2-Methylacetophenone (O-Methylacetophenone), acetophenone derivative and acaricide, is a xanthine dehydrogenase (XDH) inhibitor. 2-Methylacetophenone competitively binds to the XDH active site, blocking the pathway for xanthine to be converted to uric acid. 2-Methylacetophenone can be used for the study of hyperuricemia and house dust .

HY-Y0106R

2,6-Dihydroxyacetophenone (Standard)	Structural Classification Ketones, Aldehydes, Acids Phenols Polyphenols Endogenous metabolite Source Classification	Reference Standards mTOR Xanthine Oxidase Apoptosis
2,6-Dihydroxyacetophenone (Standard) is the analytical standard of 2,6-Dihydroxyacetophenone (HY-Y0106). This product is intended for research and analytical applications. 2,6-Dihydroxyacetophenone, a polyphenolic derivative of Acetophenone (HY-Y0989), is an orally active mTOR inhibitor. 2,6-Dihydroxyacetophenone shows antioxidant activity. 2,6-Dihydroxyacetophenone inhibits cell growth and proliferation in CRC cells. 2,6-Dihydroxyacetophenone arrests at G0/G1 phase of cell cycle, induces apoptosis and suppresses cell migration in CRC cells. 2,6-Dihydroxyacetophenone inhibits xanthine oxidase (XOD) with an IC₅₀ of 1.24 mM. 2,6-dihydroxyacetophenone improves uric acid metabolism in hyperuricemia mice, reduces plasma cholesterol in hypercholesterolemic rats, and inhibits lipid accumulation in HFD-induced obese mice. 2,6-Dihydroxyacetophenone can be used for the study of colorectal cancer (CRC), hyperuricemia and hypercholesterolemia .

HY-N17914

Smilaxchinoside A	Structural Classification Smilacaceae Smilax riparia A. DC. Plants Steroids Source Classification	Xanthine Oxidase
Smilaxchinoside A is an orally active steroidal glycoside found in the roots of S. riparia. Smilaxchinoside A reduces serum uric acid levels and shows potent uricosuric activity. Smilaxchinoside A inhibits XOD activity and downregulates renal mURAT1 expression. Smilaxchinoside A can be used for the research of hyperuricemia .

HY-164281

5-Hydroxyisourate	Structural Classification Ketones, Aldehydes, Acids Endogenous metabolite Source Classification	Nucleoside Antimetabolite/Analog
5-Hydroxyisourate is an oxidation product of Uric acid (HY-B2130), which can be catalyzed by 5-hydroxyisourate hydrolase to be converted into 2-oxo-4-hydroxy4-carboxy-5-ureidoimidazoline .